Regeneron Sees Further Growth For Eylea HD As Reimbursement Path Gets Smoother
The drug maker reported $123m in sales for the higher-dose version of Eylea in the first full quarter of sales since its approval last August.
The drug maker reported $123m in sales for the higher-dose version of Eylea in the first full quarter of sales since its approval last August.